Prospective, Multicentre, Open-Label Study Evaluating 1,5 mg/Day of Fondaparinux [fondaparinux-sodium], in Venous Thromboembolic Events Prevention in Patients With Renal Impairment and Undergoing a Major Orthopaedic Surgery. (PROPICE Study).

Trial Profile

Prospective, Multicentre, Open-Label Study Evaluating 1,5 mg/Day of Fondaparinux [fondaparinux-sodium], in Venous Thromboembolic Events Prevention in Patients With Renal Impairment and Undergoing a Major Orthopaedic Surgery. (PROPICE Study).

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2012

At a glance

  • Drugs Fondaparinux sodium (Primary)
  • Indications Venous thrombosis
  • Focus Adverse reactions
  • Acronyms PROPICE
  • Most Recent Events

    • 14 Oct 2008 Actual patient number changed from 450 to 451 as reported by ClinicalTrials.gov.
    • 14 Oct 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
    • 14 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top